News

News

December 1, 2004

Immunomedics reviews clinical advances at 2004 annual meeting of shareholders

November 3, 2004

Immunomedics announces first quarter fiscal 2005 results

Condensed Consolidated Balance Sheets

October 20, 2004

Immunomedics announces plan to conduct registration trials in lupus

October 20, 2004

Immunomedics to present at Rodman & Renshaw Techvest 6th annual healthcare conference

October 19, 2004

Immunomedics reports updated clinical results on lupus at the ACR/ARHP 68th annual scientific meeting

October 12, 2004

Immunomedics names Brian A. Markison to board of directors

September 30, 2004

Immunomedics reports research and preclinical advances at the 16th EORTC/AACR/NCI conference

September 29, 2004

Patent infringement suit settled

September 8, 2004

Immunomedics announces fiscal 2004 results

Condensed Consolidated Balance Sheets

September 8, 2004

Immunomedics to present at Bear Stearns 17th annual healthcare conference

August 2, 2004

Immunomedics, inc. raises $15 million in sale of common stock

July 7, 2004

CIS Bio international enters into a settlement with Immunomedics regarding cea antibody technology

June 23, 2004

Appeals court rules in Immunomedics’ favor; remands case to lower court for further consideration of infringement by Cytogen under the doctrine of equivalents

June 21, 2004

Immunomedics reports on radioimmunotherapy at 51st annual meeting of the Society of Nuclear Medicine

June 7, 2004

Immunomedics reports advances in lymphoma and mulitple myeloma therapy at the 40th meeting of American Society of Clinical Oncology

June 3, 2004

New data on immunomedics’ cancer therapeutics to be presented at 40th annual meeting of American Society of Clinical Oncology (ASCO)

May 11, 2004

Immunomedics announces third quarter fiscal 2004 results

Condensed Consolidated Balance Sheets

May 11, 2004

Immunomedics reports first clinical results with Epratuzumab in systemic lupus erythematosus (SLE)

April 8, 2004

Immunomedics regains north american development rights from Amgen for Epratuzumab

March 29, 2004

Immunomedics and ibc pharmaceuticals develop novel trivalent fusion protein for radioimmunotherapy

February 25, 2004

Immunomedics to present at the 7th annual Lehman Brothers Global Healthcare Conference

February 9, 2004

Immunomedics announces second quarter fiscal 2004 results

Condensed Consolidated Balance Sheets

January 26, 2004

Immunomedics reports phase II colorectal cancer therapy data at GI Cancer Symposium

January 15, 2004

Immunomedics awarded U.S. patent for humanized CEA antibody conjugates

January 13, 2004

Immunomedics to receive $10 million financing

January 7, 2004

Immunomedics to present at the 22nd annual JP Morgan Healthcare Conference